List of Excipients in Branded Drug GLIPIZIDEER

Generic Drugs Containing GLIPIZIDEER

Company	Ingredient	NDC	Excipient
Aidarex Pharmaceuticals LLC	glipizide	33261-830	ACETYLTRIBUTYL CITRATE
Aidarex Pharmaceuticals LLC	glipizide	33261-830	AMMONIA
Aidarex Pharmaceuticals LLC	glipizide	33261-830	BUTYL ALCOHOL
Aidarex Pharmaceuticals LLC	glipizide	33261-830	FD&C YELLOW NO. 6
Aidarex Pharmaceuticals LLC	glipizide	33261-830	FERROSOFERRIC OXIDE

What are the Most Frequently-Used Excipients in GLIPIZIDEER?

# Of NDCs	Excipient
1	ACETYLTRIBUTYL CITRATE
1	AMMONIA
1	BUTYL ALCOHOL
1	FD&C YELLOW NO. 6
1	FERROSOFERRIC OXIDE

Excipient Strategy and Commercial Opportunities for Glipizide ER

Last updated: February 27, 2026

What are the key excipient considerations for Glipizide ER formulations?

Glipizide Extended Release (ER) formulations require specific excipient strategies to optimize bioavailability, stability, and patient adherence. The core excipient categories include matrix formers, release modifiers, binders, fillers, and disintegrants.

Excipients in Glipizide ER formulations

• Matrix-forming polymers: Hydroxypropyl methylcellulose (HPMC), ethylcellulose (EC) provide controlled release.
• Release modifiers: Polyethylene oxide (PEO), polyvinyl acetate (PVAc) regulate drug release kinetics.
• Binders: Microcrystalline cellulose (MCC), povidone improve tablet integrity.
• Fillers: Lactose, microcrystalline cellulose serve as diluents.
• Disintegrants: Croscarmellose sodium, sodium starch glycolate facilitate tablet breakdown.

Excipient selection criteria

• Compatibility with Glipizide to prevent degradation.
• Achieving sustained release profile over 12–24 hours.
• Ensuring manufacturability on high-speed presses.
• Patient tolerability and minimize gastrointestinal irritation.

What are the commercial opportunities derived from excipient innovation?

Market landscape overview

The global oral antidiabetic drug market was valued at USD 55.3 billion in 2022, with sustained release formulations capturing an increasing share due to improved patient outcomes [1].

Potential for proprietary excipient blends

Manufacturers can develop proprietary combinations of release-modifying polymers to extend patent life, differentiate products, and command premium pricing.

Opportunities with novel excipients

• Biodegradable polymers: Offer improved safety profiles.
• Natural excipients: Appeal to demand for plant-based, clean-label medications.
• Functional excipients: Incorporation of surfactants or enzyme inhibitors for enhanced absorption.

Differentiation through formulation expertise

Formulators with advanced knowledge in controlled-release technology can create more reliable and less variable products, appealing to both branded and generic markets.

What challenges affect excipient strategies for Glipizide ER?

• Regulatory scrutiny over excipient safety, especially for novel or synthetic polymers.
• Manufacturing complexity increases with innovative excipients.
• Balancing cost against performance gains remains critical.

What is the competitive landscape?

Company	Focus	Notable formulations
Sun Pharmaceutical	Conventional and controlled release	Glipizide ER tablets
Teva	Generic and branded formulations	Glipizide ER products
Mylan	Extended release technology	Various ER formulations
Dr. Reddy’s	Innovative drug delivery systems	Controlled release Glipizide formulations

Key regulatory considerations

• Excipient safety assessments aligned with EMA and FDA guidelines.
• Documentation of compatibility and stability.
• Potential for Class 1, 2, or 3 excipients depending on the formulation complexity.

Market and patent implications

Patent expirations on GLIPIZIDE ER may prompt innovation in excipient formulation to extend market exclusivity.

Conclusions

The strategic development of excipient systems for Glipizide ER hinges on optimizing release profiles, ensuring compatibility, and navigating regulatory standards. Innovations in formulations can foster competitive advantages, increase market share, and enable higher margins.

---

Key Takeaways

• Excipient choices directly influence the release profile, stability, and manufacturability of Glipizide ER.
• Proprietary excipient blends and novel polymers offer opportunities for patent extension and product differentiation.
• Regulatory compliance on excipient safety remains a critical factor.
• Market growth in sustained-release antidiabetic drugs supports innovation in excipient technology.
• Formulation innovation can provide a competitive edge in a mature generic landscape.

---

FAQs

1. What are the primary excipients used in Glipizide ER tablets?
   Hydroxypropyl methylcellulose (HPMC), microcrystalline cellulose (MCC), croscarmellose sodium, lactose, and ethylcellulose are main excipients.

2. How does excipient choice affect Glipizide ER’s release profile?
   The excipients modulate dissolution rate and sustain drug release over desired durations, impacting absorption and therapeutic efficacy.

3. What opportunities exist in developing new excipients for Glipizide ER?
   Biodegradable polymers, natural plant-based excipients, and functional excipients with absorption-enhancing properties.

4. What regulatory challenges are linked to excipient innovation in Glipizide ER?
   Ensuring safety, compatibility, and stability of novel excipients under EMA and FDA guidelines.

5. How can excipient strategy impact the market competitiveness of Glipizide ER?
   Differentiating formulations through controlled-release technology can extend patent life and command premium prices.

---

References

[1] IQVIA Institute. (2023). The Global Use of Medicines in 2022. IQVIA.